2016
423PD Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)
Gutierrez M, Giaccone G, Liu S, Rajan A, Guha U, Halfdanarson T, Curtis K, Kunz P, Gabrail N, Hinson J, Orlemans E. 423PD Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs). Annals Of Oncology 2016, 27: vi138. DOI: 10.1093/annonc/mdw369.08.Peer-Reviewed Original Research
2015
Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
Kulke M, Niedzwiecki D, Foster N, Fruth B, Kunz P, Kennecke H, Wolin E, Venook A. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). Journal Of Clinical Oncology 2015, 33: 4005-4005. DOI: 10.1200/jco.2015.33.15_suppl.4005.Peer-Reviewed Original Research
2013
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors
Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas 2013, 42: 557-577. PMID: 23591432, PMCID: PMC4304762, DOI: 10.1097/mpa.0b013e31828e34a4.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsConsensus guidelinesNorth American Neuroendocrine Tumor SocietyPhase 3 trialTreatment of patientsHeterogeneous clinical presentationPractice-changing outcomesClinical presentationNovel agentsAnatomic locationTumorsHeterogeneous groupDegree of aggressivenessTreatmentDiseaseConsensus tableGuidelinesRigorous evaluationEverolimusSunitinibPatientsMalignancyPhysiciansTrials
2012
A renaissance in therapeutic options for pancreatic neuroendocrine tumors.
Kunz PL. A renaissance in therapeutic options for pancreatic neuroendocrine tumors. American Society Of Clinical Oncology Educational Book 2012, 271-4. PMID: 24451747, DOI: 10.14694/edbook_am.2012.32.136.Peer-Reviewed Original ResearchProgression-free survivalPancreatic neuroendocrine tumorsNeuroendocrine tumorsTherapeutic optionsRandomized placebo-controlled studyPlacebo-controlled studyNovel therapeutic optionsChemotherapy backboneLocoregional diseaseAdvanced diseaseBiologic therapySurgical resectionSomatostatin analoguesClinical trialsDrug AdministrationU.S. FoodAntiproliferative agentsTumorsDiseaseFuture studiesResectionEverolimusSunitinibPatientsOptions